Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A case study from the ROSELA trial demonstrates that the relacorilant regimen can induce profound and lasting responses. A patient with difficult-to-treat platinum-resistant disease achieved a complete response that was maintained for 22 cycles and persisted even after treatment cessation, a rare and clinically significant outcome for this patient population.
Related Insights
Subgroup analysis of the ROSELLA trial shows a consistent overall survival benefit for the relacorilant-nab-paclitaxel combination, even in patients with a short interval (<6 months) since their last taxane exposure. This crucial finding supports using the regimen as a taxane re-challenge without concern for diminished efficacy.
A consistent pattern has emerged across new trials in platinum-resistant ovarian cancer (ROSELLA, KEYNOTE-B96, MIRASOL): therapies provide only modest progression-free survival (PFS) but a more substantial overall survival (OS) advantage, suggesting a shared biological effect.
The addition of relacorilant to nab-paclitaxel offers a new standard of care for platinum-resistant ovarian cancer that benefits a broad patient population. Unlike many modern targeted therapies, its efficacy does not depend on a specific biomarker, simplifying patient selection and broadening its applicability in clinical practice.
The novel drug relacorilant overcomes taxane resistance in ovarian cancer by targeting glucocorticoid receptors. It blocks stress-induced steroid signaling that promotes anti-apoptotic proteins, effectively re-sensitizing tumors to chemotherapy. This represents a completely new mechanism of action for this patient population.
After a decade with no new therapies improving survival, the landscape for platinum-resistant ovarian cancer is transforming. The recent successes of mirvetuximab, the pembrolizumab/paclitaxel combo, and relacorilant/nab-paclitaxel have all demonstrated statistically significant overall survival benefits, heralding a new era of effective options.
Recent trials for platinum-resistant ovarian cancer, including ROSELLA (relacorilant), show a pattern of small (e.g., one month) progression-free survival gains but much larger (e.g., four months) overall survival benefits. This suggests these therapies may positively influence the long-term disease course or response to subsequent treatments.
Researchers identified a specific patient subgroup in a Phase 2 trial (1-3 prior therapies including bevacizumab) that showed a markedly stronger overall survival benefit from relacorilant. This key insight led to selecting this exact population for the pivotal Phase 3 ROSELA study, which ultimately met its primary endpoints.
High cortisol, a stress hormone, is linked to worse outcomes in ovarian cancer. Relacorilant, by blocking its receptor, appears to overcome chemo resistance by allowing the body's own immune system to help fight the cancer.
The Rosella study of relicorolant showed a striking overall survival (OS) benefit despite a modest progression-free survival (PFS) gain. This unusual pattern, often seen with immunotherapies, suggests the drug may have a delayed or immune-mediated effect beyond immediate tumor control, challenging traditional efficacy endpoints.
With multiple new effective options in platinum-resistant disease (relacorilant, pembrolizumab, ADCs), the key clinical question is shifting from choosing one superior drug to determining the optimal sequence. Biomarkers can guide initial choices, but sequencing multiple regimens, including re-using weekly paclitaxel backbones, is now a viable strategy.